Incyte to Showcase Oncology Data at 2024 ASCO and EHA Congresses

Incyte Corporation (Nasdaq: INCY) has announced the presentation of several abstracts from its oncology portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association 2024 (EHA2024) Congress. These events will take place from May 31 to June 4 in Chicago and from June 13 to 16 in Madrid and virtually.

Steven Stein, M.D., Chief Medical Officer at Incyte, expressed the company's commitment to their comprehensive research approach aimed at discovering new treatments for cancer patients. He emphasized the promise within their oncology pipeline, highlighting the need for continued therapeutic development across a range of cancers.

Key abstracts accepted for presentation at ASCO include:

1. INCB099280: A Phase 1 study of the Small-Molecule PD-L1 inhibitor INCB099280 in Select Advanced Solid Tumors. This study updates on safety, efficacy, and pharmacokinetics (PK) results (Abstract #2608) and will be presented in the Developmental Therapeutics—Immunotherapy session on Saturday, June 1.

2. INCB057643: A Phase 1 study on Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms (Abstract #6576). This will be presented in the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant session on Monday, June 3.

Key abstracts for EHA include:

1. Ruxolitinib: Several presentations focus on Ruxolitinib, including:
- Analysis of molecular mechanisms and predictive biomarkers of disease transformation in polycythemia vera (Abstract #S217).
- Real-world evaluation of risk factors for disease progression in patients with polycythemia vera enrolled in the REVEAL study (Abstract #P1047).
- The impact of new or worsening anemia on clinical outcomes in patients with myelofibrosis treated with Ruxolitinib (Abstract #P1044).

2. Zilurgisertib: Presentations will feature Zilurgisertib, including its role as an ALK2 inhibitor in combination with Ruxolitinib for treating anemia in myelofibrosis patients (Abstracts #P1019 and #P1060).

3. INCB057643: This BET inhibitor will also be discussed, focusing on patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms (Abstract #P1065).

4. INCA033989: This abstract will cover the efficacy of INCA033989 in chronic and advanced forms of CALRdel52 and CALRins5 myeloproliferative neoplasms models (Abstract #P1002).

5. INCB160058: A novel therapy for JAK2V617F mutant myeloproliferative neoplasms will be evaluated preclinically (Abstract #P1028).

6. Axatilimab: Discussed as a treatment for chronic graft-versus-host disease, focusing on responses in fibrosis-dominant organs (Abstract #P1321).

7. Pemigatinib: A Phase 2 study of Pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 gene rearrangement (Abstract #P1042).

8. Tafasitamab: Two abstracts will discuss the persistence of CD19 expression in patients with diffuse large B-cell lymphoma after treatment and the efficacy of Tafasitamab-Lenalidomide in transplant-ineligible patients with relapsed/refractory large B-cell lymphoma (Abstracts #P1234 and #P1214).

Incyte continues to develop and commercialize its proprietary therapeutics, with a strong focus on oncology and other areas of unmet medical need. Their marketed products include Jakafi (ruxolitinib), Monjuvi (tafasitamab-cxix), Pemazyre (pemigatinib), and others. Incyte's research and development efforts aim to deliver first-in-class medicines, enhancing the quality of life for patients worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!